CONTACT
+91 80 2808 2808
info@biocon.com

Company Statements 2020

Biocon  /  News – Posts  /  Company Statements  /  Company Statements 2020

Biocon Biologics Statement on the Status of Bevacizumab FDA Action Date in Dec 2020

  • Posted by: BIOCON

Biocon Biologics and Mylan Receive CHMP Recommendation for Approval of Biosimilar Insulin Aspart

Biocon Biologics and Mylan Receive CHMP Recommendation for Approval of Biosimilar Insulin Aspart
  • Posted by: BIOCON

Biocon Biologics Drug Substance Facilities in Bengaluru Receive EU GMP Certification

  • Posted by: BIOCON

Biocon Receives EIR for Small Molecules API Manufacturing Facility for Pre -Approval and GMP U.S. FDA Inspection

  • Posted by: BIOCON

Biocon Biologics Receives EIR from U.S. FDA for Two Manufacturing Facilities, Inspection Stands Closed

  • Posted by: BIOCON

Biocon’s Insulin Manufacturing Facility in Malaysia Receives EIR from U.S. FDA with Voluntary Action Indicated (VAI) Classification, Inspection Stands Closed

  • Posted by: BIOCON

Biocon Receives EIR for Small Molecules API Manufacturing Facility for Post – Approval and GMP U.S. FDA Inspection

  • Posted by: BIOCON

Biocon’s Small Molecules API Manufacturing Facility Completes Post-Approval and GMP U.S. FDA Inspection

  • Posted by: BIOCON

Biocon’s Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection

  • Posted by: BIOCON

Biocon’s Small Molecules API Manufacturing Facility Completes Pre-Approval and GMP U.S. FDA inspection

  • Posted by: BIOCON
  • 1
  • 2
Share
Previous Next
Close
Test Caption
Test Description goes like this